Kolexia
De La Fouchardiere Christelle Oncologie médicale
De La Fouchardiere Christelle
Oncologie médicale
Centre Paoli-Calmettes
Marseille, France
357 Activités
33 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Adénocarcinome Carcinomes Tumeurs de la thyroïde Métastase tumorale Instabilité des microsatellites Tumeurs du pancréas Tumeurs de l'estomac Carcinome épidermoïde

Collaborateurs

Voir plus
Tougeron David
Tougeron David
Hôpital La Miletrie, Poitiers, France
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France
Andre Thierry
Andre Thierry
Hôpital Saint-Antoine, Paris, France
Samalin Scalzi Emmanuelle
Samalin Scalzi Emmanuelle
Icm Montpellier, Montpellier, France

Industries

Voir plus
CanceroDigest
19 collaboration(s)
Dernière en 2023
Amgen
15 collaboration(s)
Dernière en 2023
Servier
13 collaboration(s)
Dernière en 2023
Roche
9 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
SCARCE: A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma
Essai Clinique (Roche)   08 mars 2024
HERIZON-GEA-01: A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Essai Clinique (Jazz Pharmaceuticals)   04 mars 2024
LIBRETTO-001: A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Essai Clinique (Loxo Oncology, Inc.)   01 mars 2024
PROFILER: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Essai Clinique (Centre Léon-Bérard)   01 mars 2024
AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.
Essai Clinique (Unicancer)   26 février 2024
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial.
Lancet (London, England)   22 février 2024
NAPOLI 3: An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas
Essai Clinique (Ipsen)   15 février 2024
SUMMIT: An Open-Label, Phase 2 Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activating HER Mutations
Essai Clinique (Puma Biotechnology)   12 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   17 janvier 2024